Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Recombinant virus encoding one or more heterologous proteins...
Reexamination Certificate
1996-08-30
2002-10-01
Scheiner, Laurie (Department: 1641)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Recombinant virus encoding one or more heterologous proteins...
C435S235100, C435S320100, C424S184100, C424S186100, C424S192100, C424S233100
Reexamination Certificate
active
06458362
ABSTRACT:
The present invention relates to recombinant viral pseudo-particles of a virus of the Parvoviridae family or of a related virus, useful in particular for inducing cytotoxic CD8
+
T lymphocyte (CTL) and CD4
+
helper T lymphocyte responses in vivo at a high level.
Another object is the use of these pseudo-particles for the production of antitumoral vaccines or drugs.
It also covers compositions comprising said pseudo-particles in a physiologically acceptable excipient and/or diluent.
According to Fernandez et al. (Médecine/Sciences, 1995, 11, 975-983), the response to cellular mediation, essential in the case of a tumor, can be divided into two parts:
on the one hand the initiation of the response which causes the involvement of the CD4
+
T lymphocytes and the cells presenting the antigen (CPA), and
on the other hand the cytotoxic effector response in which the CD8
+
T lymphocytes are involved.
The activated CD4
+
T lymphocytes proliferate and secrete cytokines while the activated CD8
+
T lymphocytes proliferate and differentiate into cytotoxic T lymphocytes (CTL).
These two families of lymphocytes thus have very different functions and are activated by distinct mechanisms. The stimulation of the CD4
+
Lymphocytes requires the association of a peptide arising from the degradation of the antigen to class II molecules of the Major Histocompatibility Complex (MHC), while those of the CD8
+
cells require the association of a peptide to class I molecules of the MHC.
A number of prophylactic or therapeutic strategies have already been proposed in attempts to control various human and animal diseases caused by viruses, bacteria, parasites, or cancerous or tumoral diseases.
For example, the induction of CTL responses in vivo by “live” vectors is known. However, the safety of these vectors is not guaranteed, particularly towards immunocompromised individuals. In addition, the systems using the replication of these “live” vectors do not retain their activity in immune individuals.
Martinez et al., teach in Vaccine (vol. 10, pp. 684-690, 1992) the use of empty capsids of pig parvovirus (PPV) in pig vaccination. The Parvoviridae family contains viruses very widely distributed in mammals such as pigs, cattle, cats, rabbits, rats and man. However, the parvoviruses are relatively specific to their host mammals. Pig parvovirus (PPV), in particular, is responsible for many infections in industrial pig breeding. Pig parvovirus (PPV) is composed of a non-enveloped isometric particle of diameter 20 nm with icosahedral symmetry, containing a single-strand DNA molecule. It is composed of two capsid proteins, VP1 (83 kDa) and VP2 (64 kDa), and a third protein, VP3, resulting from the proteolysis of VP2.
The VP2 protein can be produced by insect cells using a recombinant baculovirus system, and the VP2 proteins produced are capable of auto-assembly to form viral pseudo-particles which have the same size as the native virion. The vaccination of pigs against PPV is performed by immunizing them with a mixture of said capsids in combination with the adjuvant Alhydrogel (50%) +Quil A 500 &mgr;g (Superfos). A comparable teaching to that of this article is found in applications EP-551.449 and EP-554.414, which also disclose that antigenic determinants corresponding to other viral proteins may be incorporated into the capsids, without however specifying the nature of these antigenic determinants.
Application EP-647.655 relates to synthetic peptides corresponding to the antigenic sites of VP2. It thus does not describe the complete protein.
Attempts to modify the pseudo-particles with a view to incorporating heterologous antigenic determinants come up against difficulties such as the inhibition of the formation of the pseudo-particles. Even when the latter are formed, the heterologous antigenic determinant is not necessarily immunogenic; the antigenic determinant for example may be located in a site where it is incapable of taking up its natural conformation, or of being produced by the cells presenting the antigen.
In other respects, in the same way as vaccines with “live” vectors, the safety of these hybrid particles combined with adjuvants is not completely guaranteed, since a toxicity may arise from some properties of the adjuvants able to induce secondary effects which are harmful to the organism.
It is thus apparent from the state of the art that there is no known reliable and effective system for stimulating the cytotoxic T-lymphocyte response and or cytokine secretion, without risk to the health of the individual treated and without use of immunostimulant adjuvants.
The applicant has shown that it is possible to induce specifically a CD8
+
lymphocyte response, in other words a cytotoxic response, and/or a cytokine secretion by the CD4
+
T cells, using pseudo-particles containing antigenic determinants able to associate with at least one class I or class II molecule, respectively, of the MHC.
The object of the present invention is recombinant viral pseudo-particles produced by auto-assembly of at least one viral structural protein, having a size of between 20 and 60 nm and forming an approximately icosahedral structure, said protein being modified by the presence of at least one antigenic determinant comprising a sequence of 8 to 25 amino acids, able to associate with at least one class I or II molecule of the major histocompatibility complex (MHC), or of a combination of several of these antigenic determinants.
The CD8
+
T lymphocytes according to the invention are able to recognize at least one antigenic determinant comprising a sequence of 8 to 9 amino acids able to associate with at least one class I MHC molecule.
The CD4
+
T lymphocytes according to the invention are able to recognize at least one antigenic determinant comprising a sequence of between 8 and 25 amino acids able to associate with at least one class II MHC molecule.
Advantageously, the structural proteins comprise at least one parvovirus protein of the Parvoviridae family, or of a related virus, and preferentially at least one VP2 protein.
The particles according to the invention may also be particles composed of surface or core proteins of the hepatitis B virus, particles of poliovirus, of rabbit hemorrhagic virus, of Norwalk virus, of rotavirus, of retrovirus gag proteins (HIV, FIV, FeLV) or, in general, particles of any non-enveloped virus able to auto-assemble in vitro by the expression of one or more viral proteins.
The particles according to the invention may comprise proteins of various types, and form hybrid particles. They may for example be composed of VP1 and VP2 proteins.
The association formed between the amino acid sequence comprising the antigenic determinant and the class I and/or II molecules is recognized by the CD8
+
or CD4
+
T lymphocyte receptor and induces a differentiation and proliferation of these lymphocytes.
Advantageously, said sequence is bounded by regions known as flanking regions able to modulate its degradation, in other words to facilitate its production during the degradation of the antigen, or to facilitate its binding to class I or II MHC molecules.
The flanking regions may correspond to amino acids flanking the CD8
+
or CD4
+
T antigenic determinant in its natural environment. In general, they may be composed of several amino acids, and in particular alanine or lysine.
The pseudo-particles according to the invention have a first advantage, arising from the safety of this method of immunization, the vector used being non-replicating, consisting of a single type of viral protein and being able to be administered even to immunocompromised individuals.
A second advantage of the pseudo-particles according to the invention lies in the absence of cross-reactions with human parvovirus and thus in the absence of problems associated with a pre-immunization of the individuals, possibly leading to a weak immunogenicity of this type of recombinant vaccine.
In addition the pseudo-particles according to the inven
Casal Ignacio
Leclerc Claude
Lo-Man Richard
Rueda Paloma
Sarraseca Javier
Institut Pasteur
Parkin Jeffrey S.
Scheiner Laurie
LandOfFree
Recombinant VP2 parvoviral pseudo-particles encoding CTL or... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant VP2 parvoviral pseudo-particles encoding CTL or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant VP2 parvoviral pseudo-particles encoding CTL or... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2926769